Abstract
AbstractThe exquisite specificity of antibodies can be harnessed to effect targeted degradation of membrane proteins. Here, we demonstrate targeted protein removal utilising a protein degradation domain derived from the endogenous human protein Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9). Recombinant antibodies genetically fused to this domain drive the degradation of membrane proteins that undergo constitutive internalisation and recycling, including the transferrin receptor and the human cytomegalovirus latency-associated protein US28. We term this approach PACTAC (PCSK9-Antibody Clearance-Targeting Chimeras).
Funder
Wellcome Trust
UKRI | Medical Research Council
Deutsches Zentrum für Infektionsforschung
CIMR Flow Cytometry Core Facility
Cambridge NIHR BRC Cell Phenotyping Hub
Publisher
Springer Science and Business Media LLC